Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. North America Pharmaceutical Contract Manufacturing Market, 2019-2030, $ bn 20
Figure 6. Impact of COVID-19 on Business 24
Figure 7. Primary Drivers and Impact Factors of North America Pharmaceutical Contract Manufacturing Market 26
Figure 8. Primary Restraints and Impact Factors of North America Pharmaceutical Contract Manufacturing Market 29
Figure 9. Investment Opportunity Analysis 33
Figure 10. Porter’s Fiver Forces Analysis of North America Pharmaceutical Contract Manufacturing Market 36
Figure 11. Breakdown of North America Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, % of Revenue 42
Figure 12. North America Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%) 42
Figure 13. North America Pharmaceutical Contract Manufacturing Market: Pharmaceutical Industry, 2019-2030, $ bn 43
Figure 14. North America Pharmaceutical Contract Manufacturing Market: Biopharmaceutical Industry, 2019-2030, $ bn 44
Figure 15. Breakdown of North America Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, % of Sales Revenue 46
Figure 16. North America Addressable Market Cap in 2020-2030 by Product, Value ($ bn) and Share (%) 46
Figure 17. North America Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn 47
Figure 18. North America Pharmaceutical Contract Manufacturing Market: Branded API Manufacturing, 2019-2030, $ bn 48
Figure 19. North America Pharmaceutical Contract Manufacturing Market: Generic API Manufacturing, 2019-2030, $ bn 49
Figure 20. North America Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn 50
Figure 21. North America Pharmaceutical Contract Manufacturing Market: Solid Dosage, 2019-2030, $ bn 52
Figure 22. North America Pharmaceutical Contract Manufacturing Market: Oral Liquids, 2019-2030, $ bn 53
Figure 23. North America Pharmaceutical Contract Manufacturing Market: Parenteral/Injectables, 2019-2030, $ bn 54
Figure 24. North America Pharmaceutical Contract Manufacturing Market: Other FDFs, 2019-2030, $ bn 55
Figure 25. North America Pharmaceutical Contract Manufacturing Market: Secondary Packaging, 2019-2030, $ bn 56
Figure 26. Breakdown of North America Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, % of Sales Revenue 58
Figure 27. North America Addressable Market Cap in 2020-2030 by Phase, Value ($ bn) and Share (%) 58
Figure 28. North America Pharmaceutical Contract Manufacturing Market: Clinical Manufacturing, 2019-2030, $ bn 59
Figure 29. North America Pharmaceutical Contract Manufacturing Market: Commercial Manufacturing, 2019-2030, $ bn 60
Figure 30. Breakdown of North America Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, % of Revenue 62
Figure 31. North America Addressable Market Cap in 2020-2030 by Type, Value ($ bn) and Share (%) 62
Figure 32. North America Pharmaceutical Contract Manufacturing Market: Sterile Products, 2019-2030, $ bn 63
Figure 33. North America Pharmaceutical Contract Manufacturing Market: Non-Sterile Products, 2019-2030, $ bn 64
Figure 34. Breakdown of North America Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, % of Revenue 66
Figure 35. North America Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%) 66
Figure 36. North America Pharmaceutical Contract Manufacturing Market: Infectious Diseases, 2019-2030, $ bn 67
Figure 37. North America Pharmaceutical Contract Manufacturing Market: Oncology, 2019-2030, $ bn 68
Figure 38. North America Pharmaceutical Contract Manufacturing Market: Metabolic Disorders, 2019-2030, $ bn 69
Figure 39. North America Pharmaceutical Contract Manufacturing Market: Cardiovascular Disorders, 2019-2030, $ bn 70
Figure 40. North America Pharmaceutical Contract Manufacturing Market: Central Nervous System, 2019-2030, $ bn 71
Figure 41. North America Pharmaceutical Contract Manufacturing Market: Pulmonary Disorders, 2019-2030, $ bn 72
Figure 42. North America Pharmaceutical Contract Manufacturing Market: Gastrointestinal Disorders, 2019-2030, $ bn 73
Figure 43. North America Pharmaceutical Contract Manufacturing Market: Other Therapeutic Applications, 2019-2030, $ bn 74
Figure 44. Breakdown of North America Pharmaceutical Contract Manufacturing Market by Country, 2019 and 2030, % of Revenue 76
Figure 45. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 77
Figure 46. U.S. Pharmaceutical Contract Manufacturing Market, 2019-2030, $ bn 79
Figure 47. Canada Pharmaceutical Contract Manufacturing Market, 2019-2030, $ bn 82
Figure 48. Pharmaceutical Contract Manufacturing Market in Mexico, 2015-2030, $ bn 84
Figure 49. Growth Stage of North America Pharmaceutical Contract Manufacturing Industry over the Forecast Period 86
North America pharmaceutical contract manufacturing market is expected to grow by 5.4% annually in the forecast period and reach $62.8 billion by 2030 driven by rising need for medicines amid COVID-19 pandemic and increasing dependence on contract manufacturing organizations due to improved efficiency and productivity. Highlighted with 28 tables and 49 figures, this 110-page report “North America Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America pharmaceutical contract manufacturing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical contract manufacturing market in every aspect of the classification from perspectives of Category, Product, Phase, Type, Therapeutic Application, and Country. Based on Category, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical Industry • Biopharmaceutical Industry Based on Product, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Active Pharmaceutical Ingredients (API) • Branded API Manufacturing • Generic API Manufacturing Finished Dosage Formulations (FDF) • Solid Dosage • Oral Liquids • Parenteral/Injectables • Other FDFs Secondary Packaging Based on Phase, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Clinical Manufacturing • Commercial Manufacturing Based on Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Sterile Products • Non-Sterile Products Based on Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Infectious Diseases • Oncology • Metabolic Disorders • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Gastrointestinal Disorders • Other Therapeutic Applications Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Phase, and Therapeutic Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America pharmaceutical contract manufacturing market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Aenova Group Baxter BioPharma Solutions Boehringer Ingelheim Catalent Inc. Famar S.A. Hospira, Inc. Jubilant Life Sciences Ltd. Lonza Group Patheon Inc. Pfizer CentreSource Recipharm AB Vetter Pharma International GmbH (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More